Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments

Ann Marie Weideman, Marco Aurelio Tapia-Maltos, Kory R. Johnson, Mark Greenwood, Bibiana Bielekova · 2017

Read Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments by Ann Marie Weideman, Marco Aurelio Tapia-Maltos, Kory R. Johnson, Mark Greenwood, Bibiana Bielekova (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/openalex-w2767362256.txt.

Description

Ann Marie Weideman, Marco Aurelio Tapia-Maltos, and Kory R. Johnson, with colleagues, analyzed how age affects multiple sclerosis drugs in Frontiers in Neurology in 2017. Modern disease-modifying therapies tame the immune attacks that drive MS. Whether they keep working as patients age was an open question. The authors suspected efficacy fades as the disease evolves from inflammation toward degeneration.

They meta-analyzed all blinded, randomized trials of immunomodulatory MS drugs that reported disability outcomes. The goal was to test whether drug efficacy is independent of patient age. Their hypothesis: benefit shrinks as age and disease duration grow. They also built age-adjusted models to compare drugs fairly across trials with different patient ages. Such models could help doctors predict what a given patient stands to gain. They also help researchers correct trial results for the therapies patients received.

Catalog record

CREATORAnn Marie Weideman, Marco Aurelio Tapia-Maltos, Kory R. Johnson, Mark Greenwood, Bibiana Bielekova
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEOpenAlex / Frontiers in Neurology

Source: https://doi.org/10.3389/fneur.2017.00577

Browse the full library · About the Tower of Babel